ProCE Banner Activity

MONARCH 3 Interim OS: Abemaciclib + Nonsteroidal AI as First-line Treatment for HR+/HER2- Advanced Breast Cancer

Slideset Download
Conference Coverage
Interim results from the phase III MONARCH 3 study showed a nonsignificant improvement in OS with the addition of abemaciclib to a first-line nonsteroidal aromatase inhibitor in patients with HR+/HER2- advanced or metastatic breast cancer.

Released: September 13, 2022

Expiration: September 12, 2023

No longer available for credit.
Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Bristol Myers Squibb

Exelixis, Inc.

Gilead Sciences, Inc.

Merck Sharp & Dohme Corp.